Related Experiment Video

Updated: Oct 28, 2025

Detection of Inflammasome Activation and Pyroptotic Cell Death in Murine Bone Marrow-derived Macrophages
06:52

Detection of Inflammasome Activation and Pyroptotic Cell Death in Murine Bone Marrow-derived Macrophages

Published on: May 21, 2018

10.9K

Activation of Platelet NLRP3 Inflammasome in Crohn's Disease

Ge Zhang1, He Chen2, Yifan Guo3

  • 1NHC Key Laboratory of Glycoconjugates Research, Department of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Fudan University, Shanghai, China.

Frontiers in Pharmacology
|July 15, 2021
PubMed

Insights

Platelets in Crohn's disease (CD) show hyperactivity linked to the ROS-NLRP3 inflammasome-interleukin-1β pathway. This pathway may drive increased thrombosis risk in active CD patients.

Area of Science:

  • Immunology
  • Gastroenterology
  • Hematology

Background:

  • Patients with Crohn's disease (CD) exhibit platelet hyperactivity and a higher risk of intestinal micro-thrombosis.
  • The precise mechanisms behind platelet activation in CD remain unclear.

Purpose of the Study:

  • To investigate the assembly of the NLRP3 inflammasome in platelets of patients with active CD.
  • To determine the correlation between NLRP3 inflammasome assembly and platelet hyperactivity in CD.

Main Methods:

  • Real-time PCR and western blotting to quantify inflammasome components (ASC, NLRP3, caspase-1).
  • Flow cytometry (FCM) and ELISA to measure interleukin-1β levels, reactive oxygen species (ROS), P-selectin exposure, and fibrinogen binding.
  • Co-immunoprecipitation and immunofluorescence to assess NLRP3 inflammasome assembly.

Main Results:

  • Upregulation of ASC, NLRP3, and active caspase-1 in platelets from active CD patients compared to healthy controls.
  • Elevated serum and platelet interleukin-1β levels in active CD patients.
  • Increased NLRP3 inflammasome assembly, higher intracellular ROS levels, and enhanced platelet P-selectin exposure and fibrinogen binding in active CD patients.
  • Positive correlation between inflammasome component levels and markers of platelet activation.

Conclusions:

  • The ROS-NLRP3 inflammasome-interleukin-1β axis is implicated in platelet hyperactivity in active CD.
  • This pathway may contribute to the increased thrombotic risk observed in Crohn's disease.

Keywords:
Crohn’s diseaseNLRP3 inflammasomeROSinterleukin-1βplatelet hyperactivity

More Related Videos

Activation and Measurement of NLRP3 Inflammasome Activity Using IL-1β in Human Monocyte-derived Dendritic Cells09:04

Activation and Measurement of NLRP3 Inflammasome Activity Using IL-1β in Human Monocyte-derived Dendritic Cells

Published on: May 22, 2014

21.1K
Evaluation of Caspase Activation to Assess Innate Immune Cell Death10:23

Evaluation of Caspase Activation to Assess Innate Immune Cell Death

Published on: January 20, 2023

3.5K

Related Concept Videos

Inflammatory Bowel Disease II: Crohn's Disease01:30

Inflammatory Bowel Disease II: Crohn's Disease

Introduction
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by...
484
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
268
Inflammation01:38

Inflammation

Overview
56.7K
NF-κB-dependent Signaling Pathway02:26

NF-κB-dependent Signaling Pathway

The transcription factor NF-κB was discovered in 1986 in the lab of Nobel laureate Professor David Baltimore, for its interaction with the immunoglobulin light chain enhancer in B-cells. After more than three decades of study, it is now evident that NF-κB regulates the expression of over 100 genes. Most of these genes play an essential role in the innate and adaptive immune responses as well as the inflammatory responses of animals.
NF-κB-dependent Signaling Mechanism
The...
8.0K